Sorafenib in Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation
No Thumbnail Available
Date
2010
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to urology practice. The drugs used for management are used in a very limited number of patients and only for clear cell histology. We present a case where we administered sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, to a patient with metastatic renal cell carcinoma of clear cell histology. We found that our results were different from those of previously reported studies, because sarcomatoid differentiation was evident in a histological examination of this case. There was an excellent response to sorafenib. This case report might provide evidence that antiangiogenic agents may be active in any histological type of renal cell carcinoma. However, there are no available data to demonstrate the duration of response and survival benefit. © 2010 Elsevier.
Description
Keywords
Adult , Antineoplastic Agents , Benzenesulfonates , Carcinoma, Renal Cell , Humans , Kidney Neoplasms , Male , Pyridines , Sarcoma , alpha interferon , interleukin 2 , sorafenib , adult , article , brain edema , brain metastasis , cancer immunotherapy , cancer staging , case report , clear cell carcinoma , computer assisted tomography , hand foot syndrome , human , kidney carcinoma , lung metastasis , male , nephrectomy , postoperative care , sarcoma , survival time , tumor differentiation